ADMA Biologics Inc $ADMA Shares Sold by WINTON GROUP Ltd

WINTON GROUP Ltd lowered its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 82.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,600 shares of the biotechnology company’s stock after selling 118,784 shares during the quarter. WINTON GROUP Ltd’s holdings in ADMA Biologics were worth $214,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Western Wealth Management LLC acquired a new position in ADMA Biologics in the first quarter valued at approximately $31,000. Integrated Wealth Concepts LLC acquired a new stake in shares of ADMA Biologics during the 2nd quarter worth approximately $42,000. Quantbot Technologies LP acquired a new stake in shares of ADMA Biologics during the 2nd quarter worth approximately $51,000. Larson Financial Group LLC grew its stake in shares of ADMA Biologics by 745.1% during the 4th quarter. Larson Financial Group LLC now owns 3,262 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,876 shares during the period. Finally, Nykredit A S purchased a new position in shares of ADMA Biologics during the 2nd quarter valued at approximately $59,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Mizuho dropped their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Monday. Finally, Raymond James Financial began coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $9.11 on Friday. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $20.46. The company has a fifty day simple moving average of $9.21 and a two-hundred day simple moving average of $9.84. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49. The company has a market cap of $2.04 billion, a price-to-earnings ratio of 13.01 and a beta of 0.78.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting analysts’ consensus estimates of $0.16. The firm had revenue of $124.39 million during the quarter, compared to the consensus estimate of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The company’s revenue was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.14 earnings per share. As a group, equities analysts anticipate that ADMA Biologics Inc will post 0.78 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company’s activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA’s marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings.